MoonLake Immunotherapeutics (MLTX) Net Equity Issued and Repurchased (2023 - 2026)

MoonLake Immunotherapeutics' (MLTX) quarterly Net Equity Issued and Repurchased came in at $6.0 million in Q1 2026, down 88.57% quarter-over-quarter from $52.5 million in Q1 2024.

MoonLake Immunotherapeutics (MLTX) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends

MoonLake Immunotherapeutics' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $6.0 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 141.90 Mn
10 MoonLake Immunotherapeutics 1.35 Bn 991.29 Mn - 6.01 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 6.01 Mn
Mar 31, 2026 6.01 Mn
Mar 31, 2024 52.54 Mn
Mar 31, 2024 52.54 Mn
Jun 30, 2023 14.60 Mn
Jun 30, 2023 14.60 Mn